Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Cocktail & Poster Display session

93P - A new platform for fast-track molecular stratification of endometrial carcinomas enabling timely treatment decisions in precision oncology

Date

04 Oct 2023

Session

Cocktail & Poster Display session

Presenters

Susanne Walz

Citation

Annals of Oncology (2023) 8 (suppl_1_S5): 1-55. 10.1016/esmoop/esmoop101646

Authors

S. Walz1, C. Schanzenbach1, A. Aich1, R. Weißbach2, R. Braun1, A. Hennig1, J. Schoebel1, S. Hofmann1

Author affiliations

  • 1 Biotype GmbH, 1109 - Dresden/DE
  • 2 Biotype GmbH, 01109 - Dresden/DE

Resources

This content is available to ESMO members and event participants.

Abstract 93P

Background

Endometrial carcinomas (EC) are the most common gynecological cancer in the developed world. The original histopathology-based classification has been supplemented in the recent years by a molecular classification, based on the analysis of POLE mutation, microsatellite instability (MSI) and copy number variation. These markers have been used to develop prognostic risk groups with specific treatment options. Hence, the molecular stratification has been recommended internationally by different organizations and associations (e.g., ESMO, ESGO), allowing individualized treatment stratifications. Historically, these markers have been analyzed by various methods such as immunohistochemistry (IHC), Sanger sequencing and PCR-based fragment analysis. But the lack of single streamlined workflow has hampered the widespread adoption.

Methods

We developed three assays for discrimination of EC into ultramutated (POLE), hypermutated (MSI) and copy number high (CN high) phenotypes. CN high tumors are stratified based on molecular level with two newly identified biomarkers. We pre-characterized a patient cohort compromising of 41 samples, using IHC (MLH1, MSH2, MSH6, PMS2 and the surrogate marker TP53). Using our proprietary molecular analysis platform MODAPLEX, that unifies PCR and capillary gel electrophoresis, we analyzed this cohort with the three assays with a 4-hour turn-around time. The concordance was determined by calculation of the sensitivity.

Results

The concordance analysis of our MODAPLEX assays revealed a sensitivity of 0.923 (95% CI [0.781, 1.066]) for MSI compared to the IHC results and 0.833 (95% CI [0.622, 1.044]) for CN high compared to p53-IHC, respectively. We verified 100% of the mutations identified with the MODAPLEX POLE/POLD1 assay.

Conclusions

Overall, this study demonstrates a multi-gene/multi-marker testing workflow with complete molecular stratification for EC into a single streamlined, time- and cost-effective run. This approach will allow timely access to molecular-guided therapy for individual patients by enabling same day results, with a relative ease of implementation and fully integrated data analysis.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Biotype GmbH, Dresden, Germany.

Funding

Biotype GmbH, Dresden, Germany.

Disclosure

S. Walz, C. Schanzenbach, A. Aich, R. Weißbach, R. Braun, A. Hennig, J. Schoebel, S. Hofmann: Financial Interests, Institutional, Full or part-time Employment: Biotype GmbH.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.